Portfolio Strategy

Cogentus utilizes a capital-efficient business model that leverages inventive, highly experienced internal and external professionals to systematically and rapidly identify, evaluate and develop unique combination prescription pharmaceutical products.

The company’s products derive from leads generated internally or via external sources based on licensing and/or corporate collaborations.

Cogentus applies excellence to the elaboration of product concepts, the establishment of commercial and intellectual property strategies, and the design and execution of product development plans.

The company’s approach supports optimal probabilities of success and efficient product approvals.

Lead Development Program

CGT-2168
CGT-2168 is a unique once-daily oral formulation that combines clopidogrel* with a gastroprotectant (omeprazole) that is designed to significantly reduce the gastrointestinal side effects commonly associated with antiplatelet therapy. While antiplatelet medicines have been shown to prevent major cardiovascular events in patients with cardiovascular disease, treatment with medicines such as clopidogrel, aspirin or the frequent combination of the two, is associated with gastrointestinal bleeding, which in some cases can require hospitalization and even result in death. A Phase 3 clinical program for CGT-2168 is ongoing.

*Clopidogrel is marketed as Plavix® by Bristol-Myers Squibb Co. and Sanofi-Aventis

COGENT
The Phase 3 program for CGT-2168 is named COGENT (Clopidogrel and the Optimization of Gastrointestinal Events Trial). The COGENT program is designed to measure the incidence of upper gastrointestinal bleeding and ulcers in patients who take CGT-2168 and aspirin compared with patients who take clopidogrel and aspirin. The program is expected to enroll approximately 4,000 patients worldwide.

For more information on COGENT, please go to www.clinicaltrials.gov.

The COGENT program is overseen by a distinguished international Scientific Steering Committee.